Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Name and Address of Reporting Person*						or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Milestone Pharmaceuticals Inc. [MIST]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle) 412 WEST 15TH STREET, FLOOR 9						3. Date of Earliest Transaction (Month/Day/Year) 03/18/2020									Office below	er (give title v)		Other (below)	specify
(Street) NEW YORK NY 10011					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person					son
(City) (State) (Zip)														1 33331					
		Table	I - No	on-Deriva	tive	Se	curi	ties Ad	quire	d, Di	sposed of	f, or B	enef	icially	Own	ed			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)				Exec /Year) if an		any	med on Date, Day/Year)	3. Transa Code (8)				acquired (A) or D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price	•		Transaction(s) (Instr. 3 and 4)			
Common Shares				03/18/20	03/18/2020						2,705	A	\$10	.3618	4,309,232			I	By RTW ⁽¹⁾
Common Shares 03/19/20.					020	20			P		5,870	A	\$10	.8695	4,3	15,102		I	By RTW ⁽¹⁾
		Tal	ble II								posed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expir e (Mon	te Exe ation I th/Day		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4		11. Nature of Indirect Beneficial Ownershi (Instr. 4)
					Code	v	<u> </u>	(A) (D)	Date Exerc	cisable	Expiration Date	Title	Amou or Numb of Share	er					
		Reporting Person* MENTS, LP																	
(Last) 412 WE		(First) TREET, FLOOR	,	1iddle)															
(Street) NEW YORK NY 10			0011																
(City)		(State)	(Z	ip)															
	nd Address of	Reporting Person*																	
(Last) (First) (Middle) C/O RTW INVESTMENTS, LP 412 WEST 15TH STREET, FLOOR 9																			
(Street)																			

Explanation of Responses:

NY

(State)

10011

(Zip)

NEW YORK

(City)

^{1.} The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.

Roderick Wong, Managing

Partner

Roderick Wong By: /s/ Roderick Wong

<u>1g By: /s/</u> 03/19/2020

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).